Roth MKM downgraded Cyclacel Pharmaceuticals (CYCC) to Neutral from Buy.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYCC:
- Cyclacel reports clinical data from Phase 2 study of oral fadraciclib
- Biotech Alert: Searches spiking for these stocks today
- Cyclacel Pharmaceuticals files to sell common stock, warrants, no amount given
- Cyclacel completes enrollment in Cohort 8 of Phase 2 study of fadraciclib
- Cyclacel Pharmaceuticals confirms filing of appeal to Nasdaq delisting letter